Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Jun Ma, Jingao Li et al.|New England Journal of Medicine|2019Cited by 934
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu‐Pei Chen, Jun Ma, Xu Liu et al.|The Lancet|2021Cited by 234
Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialYou‐Ping Liu, Weiping Wen, Yihui Wen et al.|The Lancet Oncology|2021Cited by 156
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Ling‐Long Tang, Lei Chen et al.|Journal of Clinical Oncology|2022Cited by 147